Non-spinal bone SBRT achieves 93% three-year local control in oligometastatic prostate cancer

Across 401 non-spinal prostate cancer bone metastases, SBRT achieved 93.3% three-year local control, with higher dose and SIB associated with better progression-free survival.

KEY POINTS

  • This retrospective multicenter study coordinated through the DEGRO Working Group on Radiosurgery and Stereotactic Radiotherapy analyzed 317 patients with 401 non-spinal bone metastases from oligometastatic prostate cancer treated at 20 European centers between 2010 and 2024. Median age was 71 years, and median follow-up was 25.4 months. Patients with more than five bone metastases, previous irradiation of the same site, or purely palliative dose prescriptions were excluded. Most patients (78.5%) received SBRT for a single bone metastasis, and 89.8% of lesions underwent PET-based imaging before treatment.
  • Treatment prescriptions and target-volume concepts varied considerably across institutions. SBRT was delivered in 1–10 fractions, with a median fractional dose of 8 Gy (range 4–22 Gy) and total prescribed doses ranging from 18 to 50 Gy. An expanded GTV approach was used for 336/401 lesions (83.8%), while 62/401 (15.4%) received a simultaneous integrated boost (SIB). The SIB approach commonly delivered 48.5 Gy in ten fractions to the high-dose volume and 30 Gy to the surrounding low-dose volume. Median GTV mean dose was 35.7 Gy, corresponding to BED4 of 109.9 Gy. Concomitant androgen deprivation therapy was documented for 230/401 lesions (57.4%).
  • Local control was excellent despite heterogeneous dose and fractionation schedules. Only 20/401 treated metastases (5.0%) developed documented local recurrence, with Kaplan–Meier local control estimates of 98.0% at one year (95% CI 95.2–99.1%) and 93.3% at three years (95% CI 88.1–96.2%). Recurrences most frequently involved the ribs and pelvis, with eight failures each. Nineteen of the 20 recurrent lesions had been treated using the expanded GTV approach, but neither higher prescribed dose nor SIB use demonstrated a statistically significant independent association with local control.
  • Disease progression outside the treated lesion remained substantially more common than local failure. Median progression-free survival (PFS) was 29.3 months (95% CI 21.5–37.0), with 74.2% and 44.1% PFS at one and three years, respectively. Median biochemical recurrence-free survival (BRFS) was 24.9 months, with corresponding one- and three-year rates of 65.8% and 39.6%. Overall survival remained favorable, reaching 98.4% at one year and 86.3% at three years, although the cohort included patients with different oligometastatic disease states and systemic treatment exposures.
  • Higher GTV biologically effective dose was associated with improved PFS and BRFS. Exploratory subgroup analyses identified GTV mean BED4 ≥99 Gy and BED10 ≥61 Gy as associated with longer PFS (both p<0.01). In multivariable Cox analysis, each additional Gy of GTV mean BED4 was associated with lower hazards of progression or death (HR 0.99, 95% CI 0.98–1.00; p<0.01) and biochemical recurrence or death (HR 0.98, 95% CI 0.98–0.99; p<0.001). However, the dose thresholds were selected through iterative exploratory testing and should not be interpreted as validated prescription cutoffs.
  • The SIB approach was independently associated with more favorable progression outcomes, with adjusted HR 0.41 for PFS (95% CI 0.17–0.97; p=0.04) and HR 0.40 for BRFS (95% CI 0.20–0.77; p<0.01) compared with the expanded GTV approach. However, the SIB group comprised only 62 treated lesions, used different fractionation and target-volume strategies, and may have differed in disease characteristics or institutional practice. Crucially, no significant improvement in local control was demonstrated with SIB, and the observed associations cannot establish that the boost technique itself improved systemic disease outcomes.
  • Severe treatment-related toxicity was uncommon in the available records. Acute grade 3 adverse events occurred after 4/401 treatments (1.0%), comprising three pain events and one case of cystitis. Late grade 3 toxicity occurred after 2/401 treatments (0.5%), both involving rib fractures. Overall, four late fractures (1.0%) were documented, affecting the ribs or scapula, and no grade 4–5 events were reported. Interpretation is limited by retrospective toxicity collection, heterogeneous treatment and imaging protocols, incomplete information about systemic therapy and castration resistance, and potentially missed asymptomatic local failures because imaging surveillance was not standardized.

CLINICAL TAKEAWAY

SBRT provided excellent local control with a low documented incidence of severe toxicity for non-spinal bone metastases in selected patients with oligometastatic prostate cancer. Higher GTV dose and SIB use were associated with improved progression-free and biochemical recurrence-free survival, but neither demonstrated superior local control, and the nonrandomized comparisons cannot establish a treatment effect. Prospective studies are needed to determine whether larger target volumes or integrated boosts offer meaningful advantages over conventional metastasis-directed SBRT.

SOURCE

Strahlentherapie und Onkologie

Browse more research Suggest a correction